Article Sidebar

PDF
Date Published: 15/02/2023
Abstract Views: 378
Views PDF: 147
DOI: https://doi.org/10.51298/vmj.v521i2.4040
Issue
Vol. 521 No. 2 (2022)
Section
Các bài báo
How to Cite
Nguyễn, T. L., & Phạm , C. P. (2023). RESULTS OF SECOND – LINE TREATMENT OSIMERTINIB IN NON – SMALL CELL LUNG CANCER WITH EGFR MUTATION AT BACH MAI HOSPITAL. Vietnam Medical Journal, 521(2). https://doi.org/10.51298/vmj.v521i2.4040

RESULTS OF SECOND – LINE TREATMENT OSIMERTINIB IN NON – SMALL CELL LUNG CANCER WITH EGFR MUTATION AT BACH MAI HOSPITAL

Thị Lựu Nguyễn1,, Cẩm Phương Phạm 2
1 Hospital of Vietnam National University, Hanoi
2 Bach Mai Hospital

Main Article Content

Abstract

Objective: To evaluate the results of second-line osimertinib treatment in stage IV non-small cell lung cancer with EGFR mutation. Subjects and methods: A descriptive cohort study was conducted in 41 patients with EGFR mutation positive stage IV non-small cell lung cancer who failed after first- and second-generation EGFR-TKIs therapy with presence of T790M resistance mutation was treated with osimertinib at Nuclear medicine and Oncology Center Bach Mai Hospital from January 2018 to the end of February 2022 and follow up until the end of August 2022. Results: The overall response rate of osimertinib was 61%, disease control rate was 85.4%, the median progression-free survival (PFS) was 11 months, the median PFS in the group of patients with the Del 19 mutation was 11 months higher than the L858R mutant group was 6 months, difference were statistically significant, p<0.05. The most common side effects were diarrhea (41.5%), rash (39%), dry skin (26.8%), paronychia (24.4%). Most of them were mild, and no patient required a dose reduction. Conclusion: The osimertinib regimen is highly effective and safe in the second-line treatment of stage IV non-small cell lung cancer.

Article Details

Keywords

Non-small cell lung cancer, EGFR T790M mutation, osimertinib

References

1. GLOBOCAN 2020. https://gco.iarc.fr/today/data/factsheets/populations/704-viet-nam-fact-sheets.pdf
2. Keunchil Parka, Jaafar Bennounab, Michael Boyer et al. Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. Lung Cancer 132 (2019) 126–131
3. Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017;376(7):629-640. doi:10.1056/NEJMoa1612674
4. ESMO. NICE Recommends Osimertinib for Advanced EGFR T790M Mutation-Positive NCSLC. Accessed June 18, 2021. https://www.esmo.org/oncology-news/archive/nice-recommends-osimertinib-for-advanced-egfr-t790m-mutation-positive-ncslc
5. Igawa S, Ono T, Kasajima M, et al. Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study. Cancer Manag Res. 2019;11:4883-4892. doi:10.2147/CMAR.S207170
6. Auliac JB, Pérol M, Planchard D, et al. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation. Lung Cancer. 2019;127:96-102.
7. Yi L, Fan J, Qian R, Luo P, Zhang J. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis. Int J Cancer. 2019;145(1):284-294.
8. Michael Offin, Hira Rizvi, Megan Tenet, et al. Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.Clin Cancer Res.2019 Feb 1; 25(3):1063-1069.